Compare Nucor Corporation (NUE) vs Pfizer Inc (PFE) Price & Performance

Nucor (NUE) trades at $272.63, up 0.23% on the day, with a bullish technical outlook supported by moving averages and strong resistance near $280. Recent Q2 2026 earnings beat expectations with EPS of $4.84 versus $4.46, driven by record steel shipments and higher prices. Revenue trends show recovery from 2024 lows, with 2026 projections at $36.1B. The stock is near its consensus price target of $279.63, with analyst sentiment leaning bullish (59% buy ratings).

Outlook: Nucor benefits from resilient steel demand and operational efficiency, but faces risks from tariff policies and cyclical industry pressures. The current P/E of 21.76 is reasonable given earnings growth, though net margins have compressed from 2022 peaks. Investors should monitor Q3 2026 results against the $5.72 EPS estimate for continued momentum.

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.